Mexican registry of pulmonary hypertension

Abstract

REMEHIP a multicenter registry began in 2015 with a planned recruitment time of 12 months and a 4-year follow-up. The study population will comprise a longitudinal cohort study, collecting data on patients with prevalent and incident pulmonary hypertension. Will be included patients of age >2 years and diagnosis of pulmonary hypertension by right heart catheterization within Group 1 and Group 4 of the World Health Organization classification. The structure, data collection and data analysis will be based on quality current recommendations for registries. The protocol has been approved by institutional ethics committees in all participant centers. All patients will sign an informed consent form. Currently in Mexico, there is a need of observational registries that include patients with treatment in the everyday clinical practice so the data could be validated and additional information could be obtained versus the one from the clinical trials. In this way, REMEHIP emerges as a link among randomized clinical trials developed by experts and previous Mexican experience.

Demographic, hemodynamic characteristics, and therapeutic trends of pulmonary hypertension patients: The Pulmonary Hypertension Mexican registry (REMEHIP)

“…Previously, we published the REMEHIP (ClinicalTrials.gov:NCT02252705) protocol, including definitions. 1 In brief, REMEHIP is a multicenter registry collecting data on adult and pediatric, prevalent, and incident PH patients. The primary objective was to assess clinical characteristics, treatment trends, and in‐hospital and 4‐year outcomes.…”

“…Significant medical advances have occurred in the last two decades, including more systematic assessment and the availability of new therapeutic approaches to improving life quality and survival. 1 Registries in developed countries enhanced our understanding of select aspects of pulmonary arterial hypertension (PAH), including new data on epidemiology, demography, clinical presentation, treatment, and prognosis. 2 , 3 Despite the evidence from developing countries, 4 , 5 , 6 , 7 , 8 , 9 , 10 data on clinical characteristics and current care strategies in Latin American PH patients are scarce.…”

Differences in health policies for drug availability in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension across Latin America

“…The Mexican Pulmonary Hypertension Registry (REMEHIP), includes 23 centers, and it is the first prospective national registry to include incident (51.5% of cases) and prevalent (48.5%) cases of CTEPH and PAH 28 …”

“…The Mexican Pulmonary Hypertension Registry (REMEHIP), includes 23 centers, and it is the first prospective national registry to include incident (51.5% of cases) and prevalent (48.5%) cases of CTEPH and PAH. 28 Of 796 patients, 684 (85.9%) were diagnosed as Group 1 (PAH) and 112 (14.1%) as Group 4 (CTEPH), with the most frequent PAH etiologies being idiopathic PAH ( n = 248), PAH associated with congenital heart disease ( n = 112), and PAH associated with connective tissue disease ( n = 112). The median age was 41 years and 66.6% of patients were in World Health Organization functional class (WHO FC) I and II.…”

Hipertensión pulmonar en la unidad de terapia intensiva

“…Su epidemiología en el paciente mexicano se está describiendo actualmente a través de una importante iniciativa multiinstitucional contenida en el Registro Mexicano de Hipertensión Pulmonar (REMEHIP). 1 No es infrecuente en el área de la medicina crítica enfrentarse a pacientes con este problema; sin embargo, suelen confundirse en nuestro medio el caso de un paciente con diagnóstico conocido de HAP (grupo 1) por un abordaje diagnóstico previo (que incluye, entre otros, un cateterismo derecho) y que sufre en forma aguda algún problema grave sobreagregado que lo lleva a la sala de intensivos en estado crítico, y ese otro paciente críticamente enfermo, a veces antes sano, que desarrolla en el curso de su padecimiento agudo hipertensión pulmonar (HP), muchas veces del grupo 2, y sobre todo del 3, como puede ser el caso de un paciente con síndrome de insuficiencia respiratoria progresiva aguda (SIRPA). Ñamendys y sus colaboradores abordan en su trabajo un grupo de dichos pacientes, manejados en la unidad de terapia intensiva (UTI) del Instituto Nacional de Ciencias Médicas y Nutrición «Salvador Zubirán», con una prevalencia de 46.6% y sin impacto particular sobre la mortalidad (36.6%) de esta dificultad respiratoria ya de por sí catastrófica; en ellos, el nivel de la presión de la vía aérea parece haber influenciado el inicio de la HP.…”